Kidney function on GLP-1 therapy: creatinine, eGFR, the KDIGO categories, and the label's dehydration warning

Of all the tests on this site, kidney function is the one the GLP-1 labels actually tell prescribers to re-check, and they say when: whenever someone reports vomiting, diarrhea or anything else that could leave them short of fluid. This page covers the two numbers involved, what they mean, and why the warning exists.

Creatinine and eGFR

Creatinine is a waste product of muscle metabolism that the kidneys clear at a steady rate. When filtration falls, creatinine in the blood rises. MedlinePlus gives a common range of 0.7 to 1.3 mg/dL for men and 0.5 to 0.95 mg/dL for women, and notes the level varies with body size and muscle mass.

eGFR, estimated glomerular filtration rate, is calculated from creatinine, age and sex. It is reported in mL/min/1.73 m2 and is the number kidney disease is staged on. KDIGO 2024 defines the categories: G1 is 90 or higher, G2 is 60 to 89, G3a 45 to 59, G3b 30 to 44, G4 15 to 29, and G5 under 15. An eGFR under 60 for more than three months meets one criterion for chronic kidney disease; so does a persistently raised urine albumin, which is why the ADA pairs eGFR with a urine albumin-to-creatinine ratio.

BUN, blood urea nitrogen, sits next to creatinine on the panel. MedlinePlus gives 6 to 20 mg/dL. It rises with reduced filtration but also with dehydration and a high-protein intake, which makes it a useful hydration clue and a poor kidney measure on its own.

The label warning, in the labels' words

The Wegovy label, section 5.5: there have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide; the majority occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting or diarrhea; monitor renal function in patients reporting adverse reactions that could lead to volume depletion, especially during dosage initiation and escalation. The Ozempic (5.6), Zepbound (5.3) and Mounjaro (5.5) labels carry the same instruction.

Read plainly: the drug is not described as directly toxic to the kidney. The risk runs through dehydration. Nausea leads to drinking less, vomiting and diarrhea lose fluid, blood volume drops, and the kidneys are starved of flow. Anyone on a diuretic, an ACE inhibitor, an ARB or an SGLT2 inhibitor is more exposed because those drugs reduce the kidney's ability to compensate. That is the group the electrolytes and dehydration page is written for.

What FLOW showed

FLOW randomised 3,533 people with type 2 diabetes and chronic kidney disease to semaglutide 1 mg weekly or placebo. Over a median 3.4 years, the primary outcome (a composite of major kidney disease events) was 24% lower with semaglutide (331 versus 410 first events; hazard ratio 0.76; 95% CI 0.66 to 0.88). The trial was stopped early for efficacy. It is the reason the conversation about GLP-1s in kidney disease has shifted from "is it safe" toward "is it indicated", but it was a trial in a defined population on the 1 mg diabetes dose, and it does not remove the dehydration warning.

Why creatinine misleads during weight loss

Creatinine is made by muscle. Weight loss on GLP-1 therapy removes some lean mass along with fat, so creatinine production falls and the calculated eGFR rises. A rising eGFR over the first year of therapy can therefore be an artefact of a smaller muscle mass rather than a change in the kidney. KDIGO 2024 recommends cystatin C, a marker that does not depend on muscle, when creatinine-based eGFR is likely to be inaccurate. If your eGFR is near a category boundary and the number matters for another decision (a drug dose, a referral), ask whether a cystatin C based estimate would be more trustworthy.

How often

• Baseline: creatinine and eGFR on the initial CMP, before the first dose.
• Trigger: during any episode of vomiting, diarrhea or poor intake that lasts more than a day, and after it if you felt faint. This is the labels' instruction.
• Type 2 diabetes: eGFR and urine albumin-to-creatinine ratio at least once a year (ADA Standards), more often in higher KDIGO risk categories.
• Known CKD: the interval your kidney clinician sets from your KDIGO category.
• Everyone else: with the annual panel.

What to discuss with your prescriber

• Your baseline eGFR category and whether a urine albumin test was included.
• Which of your medicines make dehydration riskier, and whether any should be held during a vomiting illness (that is a "sick day" plan; ask for one).
• What symptoms should prompt a same-week renal check.
• Whether creatinine is a fair measure for you as your body composition changes.

The Tirzepatide Hub and Semaglutide Hub give the gastrointestinal reaction rates by dose from the labels, which is the practical context for how likely a fluid-losing week is. Compounded products, including those from FormBlends, are not FDA approved; the physiology behind the dehydration warning is the same, but the warning text comes from the brand labels.